SLC3A2 and breast cancer: In detail, in independent cohorts for endometrial cancer, lymphoma, colorectal cancer, and breast cancer, cytotoxic T lymphocyte was associated with better overall survival only in samples with lower SLC3A2 expression (Figures 6A–D).